Although epidermal growth factor receptor (EGFR) is highly expressed in HNSCC, the application of the EGFR inhibitor cetuximab did not improve the long-term survival outcomes of HNSCC patients. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.